Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Temozolomide +/- Pegylated Interferon-alpha 2b in Melanoma
NCT00525031Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2006
- Primary completion
- Jun 2016
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b in melanoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Clinical Response Rates (CR + PR + SD) at 8 weeks and Overall Clinical Responses at 8 weeks. Started Aug 2006; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00525031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00525031.